Phase 3 data evaluating eye implant with ranibizumab for wet AMD to be presented at ASRS
Phase 3 clinical trial from the ARCHWAY study evaluating Roche’s Port Delivery System (PDS) with ranibizumab in patients with neovascular age-related macular degeneration (wet AMD), will be presented Sunday, July 26, at the American Society of Retina Specialists Annual Meeting.
The eye implant, which continuously delivers a customized formulation of ranibizumab over an extended period, demonstrated non-inferior and equivalent visual acuity outcomes compared with monthly eye injections of ranibizumab.
“Based on the Archway results, PDS could potentially reduce the number of treatments from as many as 12 per year to two per year for neovascular AMD patients, without sacrificing efficacy,” said Carl Regillo, MD, Chief of Retina Service at Wills Eye Hospital in Philadelphia and an Archway study investigator, in a press release. “While effective therapies exist for this condition, I know from clinical experience that it can be difficult for patients and caregivers to commit to frequent treatments, and patients who are not treated frequently enough may be at risk of losing vision.”
The study will be presented on Sunday, July 26 in the Wet AMD Symposium starting at 10:30 AM.
Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) for Patients With Neovascular AMD, Peter Campochiaro, MD
